Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job
Vaccine skepticism concerns impact biotech investor sentiment
Shares of European drug makers fall, along with U.S. companies
Analysts worry about RFK Jr.'s influence on HHS agencies
Updates throughout with detail on stock moves
By Samuel Indyk and Ludwig Burger
Nov 15 (Reuters) -Shares of major U.S. drugmakers fell on Friday after President-elect Donald Trump picked anti-vaccine activistRobert F. Kennedy Jr. to head the Department of Health and Human Services, the top U.S. health agency.
Kennedy has been criticizedfor making false medical claims, including that vaccines are linked to autism.
Kennedyhas also vowed to purge the U.S. Food and Drug Administration, remove fluoride from public water supply, and take a strong stand against ultra-processed food.
Shares of biotechnology and pharmaceutical companiesfell, with the S&P 500 Pharmaceuticals index .SPLRCCARD down about 2%. Shares of packaged food and beverage giants such as Pepsi PEP.O and Coca-Cola KO.N also declined.
Vaccine makers were the worst hit on Friday, declining for a second day following the announcement of Kennedy's appointment. Moderna MRNA.O shares fell almost 7% after hitting their lowest level sinceApril 2020. Shares of Moderna, which makes vaccines for COVID-19 and for respiratory syncytial virus, have tumbled about 30% since Trump's election victory on Nov. 5.Rival Pfizer PFE.N shed 4.5% on Friday,while Novavax NVAX.O, whose only product is a COVID vaccine, lost almost 2%.
"The point is around sentiment, stance and perspective - that impacts biotech investors' view of how FDA and other HHS issues will evolve (ie not accelerating drugs and pro-biotech)," Jefferies analysts said in a note.
'FAR-REACHING IMPLICATIONS'
European pharma majors also came under pressure as investors assessed the implications of Kennedy'spotential appointment to the top health job in U.S., the world's biggest drug market.
German-listed shares of BioNtech 22UAy.DE, Pfizer's partner on COVID-19 vaccines, tumbled more than 10%. Its U.S.-listed stock fell almost 4%. GSK GSK.L shares fell 3.9% and French drugmaker Sanofi shed 3.3%.
Sartorius SATG.DE, a major supplier of biotech lab gear and substances, fell almost 6%.Bavarian Nordic BAVA.CO, which makes a vaccine for mpox, tumbled 17%, also hurt by third-quarter results.
Bavarian Nordic'sCEO said he expects the Trump administration to boost biodefense funding despite the nomination of Kennedy.
J.P. Morgan analysts cited the potential impact on agencies that are part of HHS, including the Centers for Disease Control and Prevention, the National Institutes of Health, and Medicare and Medicaid, as well as the FDA.
"We are not surprised the sector has been under pressure on the potential for RFK Jr. having oversight of the various agencies within HHS (including the FDA, the CDC, NIH, and Medicare/Medicaid) given his previous stated views on the industry," the J.P. Morgan analysts wrote in a note, adding that itwas too early to evaluate the exact impact.
Several medical scientists on Friday voiced alarm that vital vaccination efforts could be undermined.
Kennedy'sappointment could have "far-reaching and difficult-to-project implications for the biotechnology sector, adding a considerable layer of uncertainty and challenging investability," RBC analyst Brian Abrahams said.
Makers of obesity drugs were also pressured, withNovo Nordisk NOVOb.CO dropping more than 5%, RocheHolding ROG.S downmore than 2%, andEli Lilly LLY.N losing about 4%.
Kennedy has criticized the popular Novo Nordisk drug Ozempic, which is often prescribed for weight loss, saying it focused on symptoms of the obesity crisis rather than improving the food system.
Kennedyhas called for removingultra-processed foods fromschool lunches as part of a goal to reduce the incidence of diet-related chronic diseases.
U.S. packaged food companies such as Hershey HSY.N, General Mills GIS.N, Conagra Brands CAG.N and Kraft Heinz KHC.O were down more than 3% each.
Shares of beverage makers Coca-Cola, PepsiCo, Monster Beverage MNST.O and Keurig Dr Pepper KDP.O fell around 4%.
However, shares of consumer goods companies Procter & Gamble PG.N, Colgate-Palmolive CL.N and Church & Dwight CHD.N, which make toothpastes, among other products, roseabout 2% on a day when the broader stock market wasdown.
Trump's health team: Who could be in the running? https://www.reuters.com/world/us/who-could-be-running-trumps-health-team-2024-11-14/
Vaccine makers fall as Trump taps RFK Jr for US health job https://tmsnrt.rs/4eESfZS
FACTBOX-RFK Jr.'s plan for changing the U.S. food and drug system nL1N3ML1CS
Reporting by Samuel Indyk in London, Ludwig Burger in Frankfurt, Sriparna Roy and Ananya Mariam Rajesh in Bengaluru; additional reporting by Noel Randewich in Oakland, California; Editing by Alun John, Mark Potter, Louise Heavens, Sriraj Kalluvila and Leslie Adler
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
